Earnings Call · Q4 FY2021·2021-11-22

Q4 21EPS -2.52%·Rev n/aQ3 21EPS +7.75%·Rev n/aQ2 21EPS -12.37%·Rev n/aQ1 21EPS +46.75%·Rev n/a⚠ consensus missing

ENANTA PHARMACEUTICALS INC ENTA

Jennifer Viera — Investor Relations

Jay Luly — President and Chief Executive Officer

Paul Mellett — Chief Financial Officer

+15.1%1d on move date+14.9% vs SPY3d+22.2%5d+17.4%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ENTA calls or request research access.

More ENTA calls Browse calls Request research access